Scilex Holding Company Selling, General and Administrative Expense
Scilex Holding Company (SCLX) reported Selling, General and Administrative Expense of $27.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-14
- Scilex Holding Company selling, general and administrative expense for the quarter ending 2026-06-30 was $27.96M, a 40.92% increase year-over-year.
- Scilex Holding Company selling, general and administrative expense for the quarter ending 2026-03-31 was $31.03M, a 10.60% increase year-over-year.
- Scilex Holding Company selling, general and administrative expense for the quarter ending 2025-12-31 was $30.16M, a 14.82% decline year-over-year.
- Scilex Holding Company selling, general and administrative expense for the quarter ending 2025-09-30 was $188.82M, a 535.04% increase year-over-year.
- Scilex Holding Company selling, general and administrative expense for fiscal 2025 was $266.88M, a 124.24% increase from fiscal 2024.
- Scilex Holding Company selling, general and administrative expense for fiscal 2024 was $119.02M, a 0.52% decline from fiscal 2023.
- Scilex Holding Company selling, general and administrative expense for fiscal 2023 was $119.64M, a 84.36% increase from fiscal 2022.
- Scilex Holding Company selling, general and administrative expense for fiscal 2022 was $64.89M, a 28.30% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.96M 10-Q · filed 2026-08-14 | $58.99M 10-Q · filed 2026-08-14 | $89.15M derived: sum of 3 quarters · filed 2026-08-14 | $277.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $31.03M 10-Q · filed 2026-05-20 | $61.19M derived: sum of 2 quarters · filed 2026-05-20 | $250.02M derived: sum of 3 quarters · filed 2026-05-20 | $269.86M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $30.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $218.98M derived: sum of 2 quarters · filed 2026-04-10 | $238.82M derived: sum of 3 quarters · filed 2026-08-14 | $266.88M 10-K · filed 2026-04-10 |
| 2025-09-30 | $188.82M 10-Q · filed 2025-11-14 | $208.66M derived: sum of 2 quarters · filed 2026-08-14 | $236.72M 10-Q · filed 2025-11-14 | $272.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $19.84M 10-Q · filed 2026-08-14 | $47.90M 10-Q · filed 2026-08-14 | $83.31M derived: sum of 3 quarters · filed 2026-08-14 | $113.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $28.06M 10-Q · filed 2026-05-20 | $63.47M derived: sum of 2 quarters · filed 2026-05-20 | $93.20M derived: sum of 3 quarters · filed 2026-05-20 | $117.80M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $35.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $65.14M derived: sum of 2 quarters · filed 2026-04-10 | $89.74M derived: sum of 3 quarters · filed 2026-04-10 | $119.02M 10-K · filed 2026-04-10 |
| 2024-09-30 | $29.73M 10-Q · filed 2025-11-14 | $54.33M derived: sum of 2 quarters · filed 2025-11-14 | $83.61M 10-Q · filed 2025-11-14 | $107.13M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $24.60M 10-Q · filed 2025-08-13 | $53.88M 10-Q · filed 2025-08-13 | $77.40M derived: sum of 3 quarters · filed 2025-08-13 | $117.83M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $29.28M 10-Q · filed 2025-05-14 | $52.80M derived: sum of 2 quarters · filed 2025-05-14 | $93.23M derived: sum of 3 quarters · filed 2025-05-14 | $120.22M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $63.95M derived: sum of 2 quarters · filed 2025-03-31 | $90.94M derived: sum of 3 quarters · filed 2025-03-31 | $119.64M 10-K · filed 2025-03-31 |
| 2023-09-30 | $40.43M 10-Q · filed 2025-01-17 | $67.42M derived: sum of 2 quarters · filed 2025-01-17 | $96.12M 10-Q · filed 2025-01-17 | $119.64M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $26.99M 10-Q · filed 2024-08-13 | $55.69M 10-Q · filed 2024-08-13 | $79.21M derived: sum of 3 quarters · filed 2024-08-13 | $95.33M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $28.70M 10-Q · filed 2024-05-13 | $52.23M derived: sum of 2 quarters · filed 2024-05-13 | $68.34M derived: sum of 3 quarters · filed 2024-05-13 | $82.69M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $39.64M derived: sum of 2 quarters · filed 2024-03-12 | $53.99M derived: sum of 3 quarters · filed 2024-03-12 | $64.89M 10-K · filed 2024-03-12 |
| 2022-09-30 | $16.12M 10-Q · filed 2023-11-14 | $30.46M derived: sum of 2 quarters · filed 2023-11-14 | $41.37M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $14.34M 10-Q · filed 2023-08-11 | $25.25M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $10.91M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $50.58M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $42.97M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |